Recorded April 11 Traders Network Interview of BioSculpture Technology’s CEO Dr. Robert Cucin
April 13, 2015CEO, Robert L. Cucin is interviewed by Michael Yorba on the I Heart Radio’s “Traders Network Show” on April 11, 2015.
Dr. Cucin discusses the rationale and potential of the endoscopic visceral lipectomy methods and devices the company is developing for the treatment of obesity, metabolic syndrome and type 2 diabetes.
Our patented technology will make it possible to remove fat WITHIN the belly safely.
October 19, 2014BioSculpture Technology’s patented technology now makes it possible to safely and efficiently remove visceral or “belly” fat inside the abdomen for the first time. This method has the potential of becoming a safer and highly effective alternative to current bariatric surgical treatments of obesity, metabolic syndrome and type 2 diabetes mellitus.
November 8, 2013
November 5, 2013 Press Release – U.S. Patent 8,574,223 issued protecting a Method of Collecting and In Situ Processing of Tissue Sampled from Human Patients During Aspiration Operations.
The patent describes a method and device that allows collection of processing of fat in isolated samples for analysis or autografting.
The clinical significance of this patent is that it facilitates and teaches the sampling of fat to ascertain the location and collections of fat which are the most noxious, specifically those that are producing the cytokines or cellular hormones which are responsible for metabolic syndrome and the morbidities associated with obesity.
There is a vastly different metabolic significance of fat with the different body compartments, with visceral fat being the most hazardous, probably because of its drainage into the portal circulation. Fat in different locations within each compartment is likely to vary in metabolic significance as well. It is logical to adopt a “worst first” fat removal sequence to maximize any potential health benefits.
Campaign to Kick Start Development of Less Invasive Obesity Treatment
June 24, 2013BioSculpture Technology, Inc. initiates a campaign to kick start development of the treatment contemplated by two recently issued U.S. patents to endoscopically removal visceral fat.
Visceral fat is a noxious hormone factory secreting cytokines which make obese and overweight patients insulin resistant and develop type 2 diabetes mellitus, hypertension, slows their metabolism, and promotes coronary artery disease, inflammatory diseases and cancers. The literature and some early clinical studies have shown removing it has immediately beneficial effects in reversing those metabolic effects.
Please take the time to learn more about this and help us bring it to the 1.3 billion people whom it can benefit faster.
http://www.indiegogo.com/project/445739/widget/3646746
BioSculpture Technology, Inc. Private Placement
March 21, 2012BST now has numerous pipeline products under development and 21 pending international andU.S.patent applications with claims relating to:
- Improved TCAL designs for more efficient aspiration;
- Synchronization of tumescence and bipolar cautery with aspiration;
- Collection, concentration, processing, and reinjecting syringes and in-line chambers and methods;
- Endoscopic fat removal devices and methods for treating abdominal obesity, metabolic syndrome, and type II Diabetes Mellitus.
- An internet-based network supporting the harvesting, photoactivation, cataloguing, tracking, and managing of aspirated fat tissue samples including stem cells.
- Device and method for photo-activating an aspirated sample of tissue within a tissue collection and processing system.
You can view BST product offerings, read a white paper discussing clinical results, a surgical video of them in use, and illustrative animations of twin cannula reciprocation and the Airbrush(R) Liposculptor II on the company website.
BST has engaged the Maxim Group as its investment banker to make a private placement of $10 Million Dollars its equity for the company’s expansion.
IN3 Medical Device Conference March 2, 2012 in Orlando
March 21, 2012BST was invited to present an update of its progress at Elsevier’s IN3 Medical Device 360 degrees March 2, 2012 at the Ritz-Carlton Orlando Grande Lakes in Orlando, Florida.